WellPrept
Decision Aid

Localized prostate cancer: choosing a treatment

Your cancer is still inside the prostate. That usually means you have time, and you have choices. This page compares the five paths on cancer control, recovery, and side effects.

Last reviewed 2026-06-09 Reading time ~10 min Print-friendly
A note before you start

This tool does not pick for you. Your urologist and your care team will help you choose.

Use what is below to sort your own priorities before your visit. How much does removing the cancer now matter to you, set against the side effects that come with it? How much do you want to protect how you pee and how sex works? Your team knows your PSA, your Grade Group, your risk group, your age, and your other health. They are the ones who can fit any of this to you. No single path here is the right answer for every man.

Chapter 1 · The decision

What this decision is about

A biopsy has shown prostate cancer. Your scans and exam suggest it is still inside the prostate, with no sign it has spread to lymph nodes or other organs. Doctors call this localized prostate cancer. It is the most common way prostate cancer is found.

Many men feel a strong pull to "just get it out" the moment they hear the word cancer. For some men that instinct fits. For many others, especially those with slow-growing, low-risk cancer, treatment carries side effects that watching closely would have spared them. Most localized prostate cancer grows slowly, so you usually have a few weeks to read, ask questions, and get a second opinion before you decide.

Several paths are reasonable for most men. Which one fits depends on your cancer, your body, and what you care about.

What your care team brings to the choice

Your team weighs many things at once: your PSA, your Grade Group (how the cancer looks under the microscope), and your NCCN risk group, which pulls those together. They also weigh your age, your other health, and how long you are likely to live with and without treatment. Then there is what you most want to protect: how you pee, how sex works, your bowel, or simply avoiding the side effects of treatment for as long as the cancer lets you. They will tell you which paths are reasonable for your cancer. This tool assumes that talk is starting or already going.

Chapter 2 · The five paths

Compare the five main paths

These are the five paths men with localized prostate cancer choose between. Not all five are on the table for every man. Your risk group (Chapter 5) decides which ones are. Read down a column to learn one path. Read across a row to compare them on one thing.

Path 1Active surveillance Path 2Surgery Path 3Radiation Path 4Focal therapy Path 5Watchful waiting
What it is Watching the cancer closely with a set schedule of PSA blood tests, MRI scans, and repeat biopsies. Treatment starts only if the cancer shows signs of changing. Removing the whole prostate and the seminal vesicles. The cancer goes with the organ. Done open or with a robot (Chapter 3). High-energy radiation aimed at the prostate, from a machine outside the body or from sources placed inside it. Several types (Chapter 3). Treating only the part of the prostate that has cancer, leaving the rest, to spare urine and sexual function. Newer and less proven. Not treating the cancer itself, and not the close monitoring of active surveillance either. Watching for symptoms and treating those if they come. Different from Path 1.
What it asks of you Sticking to the testing schedule, including repeat biopsies, for years. Living with the cancer still in place. The hardest part for many men is the worry between tests. One operation, general anesthesia, a catheter for about a week, and a recovery measured in weeks. Side effects come right away and then improve. Many short daily sessions over weeks, or a few larger ones, depending on type. A setup and travel commitment. Side effects build slowly over months to years. A procedure, then ongoing surveillance of the untreated prostate, because cancer can appear in the part that was left. Insurance may not cover it. Little upfront. You accept that the goal is comfort and function, not curing the cancer. Treatment is used later only to ease symptoms.
What it gives back No side effects from treatment unless and until you switch. You keep how you pee and how sex works while the cancer stays quiet. The prostate and its cancer are removed. The PSA should drop to undetectable, which makes follow-up clear. Pathology gives an exact read on the cancer. Strong cancer control without surgery. No incision and no hospital stay for most types. Often paired with hormone therapy in higher-risk disease. Because most of the prostate is left alone, more men keep urine control and erections than after whole-gland treatment, while the main tumor is still treated. You are spared the testing, procedures, and side effects of active treatment for a cancer unlikely to affect your lifespan.
How well it works For low-risk cancer, watching does not raise the chance of dying of prostate cancer over 15 years (the ProtecT trial). Some men move to treatment later, and most can still be cured. Strong, durable cancer control for localized disease. For most men, the chance of dying of prostate cancer over 15 years is similar to radiation and to watching low-risk cancer. Strong, durable cancer control, broadly similar to surgery for localized disease. Higher-risk cancers usually add hormone therapy to improve control. Short-term cancer control looks reasonable in the right patient. Long-term results past 10 years are limited. Cancer can return in the untreated part. Not aimed at controlling the cancer. Chosen when the cancer is unlikely to shorten your life before something else would.
Sex and urine, in short Unchanged while you stay on this path. Leaking is common at first and improves over 6 to 18 months. Ejaculation ends. Erections recover slowly over 1 to 2 years, more so with nerve-sparing. Less leaking up front than surgery. New erection trouble and bowel changes build over 1 to 3 years. Ejaculation fades over time. Urine control and erections are kept in most men. The lowest functional cost of the active treatments, in the right patient. Unchanged by this path. Symptoms are treated if they arise.
Reversible? Fully. You can switch to any treatment path at any time. No. The prostate cannot be put back. Radiation is still possible afterward if needed. No. The tissue is permanently changed. Surgery after radiation is harder and less common. The treated area is permanent, but the rest of the prostate is intact, so other treatments stay open. Fully. You can move to active treatment if your situation or your wishes change.
Who it tends to fit Very low, low, and select favorable intermediate-risk cancer. Men comfortable living with a watched cancer. Intermediate and high-risk cancer, and younger men who want the prostate out and accept the recovery. Reasonable across many risk groups. Intermediate and high-risk cancer, men who want to avoid surgery, and men whose health makes an operation harder. Selected men with a single area of intermediate-risk cancer who accept ongoing surveillance. Not used for low-risk (watching fits) or high-risk (cancer is usually spread through the gland). Men whose age or other health makes them unlikely to live long enough for the cancer to cause trouble, or who do not want treatment.
What active surveillance involves

It is easy to hear "we will watch it" and feel you are being asked to ignore a cancer. You are not. Active surveillance is a structured plan with regular PSA tests, MRI scans, and repeat biopsies, plus a clear trigger to treat if the cancer changes. For low-risk cancer, it is the path most guidelines point to first. Watchful waiting (Path 5) is a separate thing, for men unlikely to need treatment at all.

Chapter 3 · Surgery and radiation up close

Within surgery and radiation, you have more choices

Two of the five paths open into a set of their own. If you lean toward surgery, you will pick how it is done. If you lean toward radiation, you will pick which kind. These choices change the daily commitment and the side-effect pattern more than they change cancer control.

Within surgery: how the prostate is removed

The cancer control is similar across surgical approaches. In skilled hands, the differences show up in blood loss, recovery, and the surgeon's own experience, not in whether the cancer comes back. Surgeon experience matters more than which tool is used.

Approach ARobot-assisted Approach BOpen
What it is The surgeon works at a console, guiding robotic arms through several small cuts. The most common approach in the US. The prostate is removed through one cut in the lower belly. Less common now, with cancer results that match the robot in experienced hands.
Hospital stay Usually one night, sometimes same-day. Often one to two nights.
Blood loss & recovery Less blood loss and a quicker early recovery for most men. Back to light activity in a couple of weeks. More blood loss on average and a somewhat longer early recovery. Full recovery still measured in weeks.
Catheter About a week, then removed in the office. About a week, similar to the robot.
Urine control arc Most men leak right after the catheter comes out. About 8 or 9 in 10 reach little or no leaking by 12 months. Pelvic floor exercises help. The same arc and similar 12-month numbers. The approach is not what drives continence; the surgeon and your anatomy are.
Erection arc Erections recover slowly over 1 to 2 years and depend heavily on nerve-sparing (below) and your erections before surgery. Often helped by pills or other aids. The same slow arc, driven by nerve-sparing and your starting point, not by open-versus-robot.
What the evidence shows Large comparisons show similar cancer control and similar long-term urine and erection outcomes between robotic and open surgery. The robot tends to mean less blood loss and a faster early recovery. Pick a surgeon who does many of these, by whichever route they are most practiced in.
The nerve-sparing question

The nerves that drive erections run right alongside the prostate. During surgery, your surgeon decides whether to spare both, one, or neither. The call depends on where your cancer sits and how far it reaches. Sparing the nerves, when it is safe to do so, is the strongest thing in a surgeon's control for erections recovering afterward.

When the cancer hugs the nerves, sparing them can leave cancer behind, so the surgeon may not be able to. Ask where your cancer sits and whether nerve-sparing is on the table for you. It is one of the most useful questions you can bring to a surgical visit.

Within radiation: which kind

These differ most in the time commitment and the side-effect pattern. Cancer control is broadly similar for localized disease when the right type fits the cancer. Higher-risk cancers often add hormone therapy to radiation. That is a separate decision, covered in the guide.

Type AExternal beam (IMRT, SBRT) Type BBrachytherapy (seeds, HDR) Type CProton therapy
What it is Radiation aimed from a machine outside the body. IMRT shapes the beam precisely. SBRT delivers larger doses in far fewer sessions. Radiation from sources placed inside the prostate. LDR uses permanent seeds; HDR uses temporary catheters that deliver a dose and come out. External radiation using protons instead of standard X-rays. The physics differs; the practical results land close to standard external beam.
Number of sessions IMRT: about 20 to 44 daily sessions over 4 to 9 weeks. SBRT: about 5 sessions over 1 to 2 weeks. LDR seeds: one outpatient procedure. HDR: one to a few sessions, sometimes added to external beam. Similar session count to IMRT, depending on the schedule used.
Setting Outpatient radiation visits. No incision. A short daily appointment each time. An outpatient procedure in the operating room, usually with anesthesia. Outpatient visits at one of the fewer centers that have a proton machine.
Side-effect pattern Early on: urine frequency and urgency, looser stools, fatigue. Later, over years: bowel changes in some men, new erection trouble that builds slowly. A spacer gel can lower bowel effects. Urine frequency and weak stream peak around 1 to 3 months and ease over the year. Bowel effects are usually less than external beam. Erection trouble builds over 3 to 5 years. Broadly similar to external beam. Claims of fewer side effects are not settled by head-to-head evidence.
What the evidence shows Long track record. SBRT's shorter schedule shows similar control to longer courses in low and intermediate-risk disease. Strong control as a standalone for lower-risk cancer, or added to external beam as a boost for higher-risk cancer. Fewer centers offer HDR. Costs more and is offered at fewer centers. Head-to-head evidence that it works better than standard external beam on outcomes or side effects is not settled.
Who it tends to fit A wide range of localized cancers. SBRT suits men who want the fewest visits and whose cancer fits it. Seeds fit smaller prostates and lower-risk cancer with mild urine symptoms. HDR boost is used in higher-risk cancer. Men with access to a proton center who weigh the cost and the unsettled evidence and still prefer it.
A note on focal therapy

Focal therapy (such as HIFU or cryotherapy) treats only the part of the prostate with cancer. It is the newest path here and the least settled. Long-term results past 10 years are limited, insurance coverage varies, and cancer can show up later in the untreated part, so you keep getting surveillance. For the right man with a single area of cancer, it is a reasonable option to discuss. It is not a sure cure, and the evidence behind it is weaker than for surgery or radiation.

Chapter 4 · Sex, urine, and bowel

The side effects men weigh most

For most men with localized cancer, the paths are about equally good at controlling the cancer. So the decision often turns on side effects, and above all on how they affect sex, peeing, and the bowel.

Surgery and radiation do not cause their side effects at the same time.

  • Surgery causes its effects right away. Leaking and erection trouble start the day the catheter comes out, then improve over the next 1 to 2 years, more for some men than others.
  • Radiation causes fewer effects up front. But new bowel, urine, and erection trouble can show up or get worse slowly. This can go on over 1 to 3 years and beyond.
  • Active surveillance and watchful waiting change none of this, for as long as you stay on them.

The pictures below show roughly how many men out of 100 have lasting new erection trouble with each active path. These are typical ranges from large studies. Your own odds depend on your age, your erections before treatment, your cancer, and nerve-sparing.

Surgery

Bilateral nerve-sparing, healthier man

Around 30 to 50 of 100 still have erections firm enough for sex at 1 to 2 years, often with the help of pills. Ejaculation ends after surgery for everyone.

Radiation

External beam or brachytherapy

About 30 to 50 of 100 develop new erection trouble. It tends to come on slowly over 3 to 5 years, not right away. Hormone therapy, when added, lowers sex drive and erections while you are on it.

Active surveillance

Watching, no treatment yet

None from the path itself. Your sex life and peeing stay as they are. The cost here is the worry of a watched cancer, not a physical side effect.

The numbers are typical ranges, not promises for your case.

Active surveillance Surgery External beam radiation Brachytherapy Focal therapy
Urine control at 1 year Unchanged. About 8 or 9 in 10 have little or no leaking; a small share need more help. Most keep control; a small share get new urine frequency or urgency. Most keep control; urine symptoms are common in the first year, then ease. About 95 in 100 keep control.
Erections at 1 to 2 years Unchanged. About 30 to 50 in 100 firm enough for sex, more with nerve-sparing and PDE-5 pills. New trouble in about 30 to 50 in 100, building slowly over years. New trouble in about 30 to 50 in 100 over 3 to 5 years. More often kept than after whole-gland treatment; new trouble in roughly 10 to 30 in 100.
Ejaculation Unchanged. Ends. Orgasm is still possible but dry. Some men leak a little urine at orgasm early on. Volume drops over time; many men become dry by about 5 years. Reduced volume. Often kept, with less volume.
Bowel Unchanged. Unchanged. New bowel changes (loose stools, urgency, rare bleeding) in about 5 to 15 in 100; a spacer gel lowers this. Less than external beam. Rare.
When effects show Not applicable. Right away, then improve over 6 to 18 months. Slowly, over 1 to 3 years and beyond. Urine early; erections over years. Usually mild and early.
What men do not always hear up front

After surgery, ejaculation ends, orgasm becomes dry, and some men notice the penis is a little shorter. Some men leak a little urine at orgasm in the first year. After radiation, side effects can keep changing for years, and there is a small rise in the risk of a new bladder or rectal cancer over decades, which matters more for a man in his 50s than in his 70s, and a small number of men get lasting bladder irritation or occasional blood in the urine years later, called radiation cystitis. If you are younger and may still want children, ask about banking sperm before treatment.

Chapter 5 · How your risk group narrows the paths

Your risk group decides which paths are on the table

Not all five paths are reasonable for every man. Which ones are depends on your risk group, a rating your team builds from your PSA, your Grade Group, and how the cancer looks on exam and biopsy. This aid does not tell you your group. Your urologist does. But it helps to know how the group changes your options.

The system most US teams use is called NCCN. It sorts localized prostate cancer into bands, from very low risk up to very high risk. The lower your risk, the more watching is on the table. The higher your risk, the more treatment, and sometimes hormone therapy added to radiation, comes into the picture.

RiskYour risk group What the options usually look like
Very low or low Active surveillance is the path most guidelines point to first. Surgery and radiation stay available if you and your team prefer them or if the cancer changes later.
Favorable intermediate Active surveillance fits some men here. Surgery and radiation are both reasonable. Focal therapy may come up for a single area of cancer. Hormone therapy is usually not added to radiation.
Unfavorable intermediate Surgery or radiation. Short-term hormone therapy is often added to radiation. Watching is generally no longer the first choice.
High or very high Surgery (often with lymph node removal) or radiation with longer hormone therapy. A team review across urology and radiation oncology is standard. Ask whether a clinical trial fits your case.
Ask for your risk group, in those words

Ask on the first visit: "What is my NCCN risk group, and how does that shape what you are recommending?" The answer tells you which of the five paths are options for you, so you can spend your reading time on the ones that apply to you.

Chapter 6 · Your trade-offs

What you are weighing

The right choice depends on your risk group and on what you most want to protect. Ask yourself:

  • If watching is on the table for me, can I live with a cancer that stays in place while we keep an eye on it?
  • How much does having the cancer removed, and knowing it is out, matter to me?
  • How much do I want to protect erections and how sex works? How much does my partner figure into that?
  • How much do I want to protect how I pee, and avoid the leaking that can follow surgery?
  • Would I rather have side effects come and then improve, as with surgery? Or stay light up front and build slowly over years, as with radiation?
  • Can I commit to weeks of daily radiation visits? Or do I want a single procedure and one recovery?
  • How do I weigh my age and my other health against how long this cancer is likely to take to cause trouble?
  • If I still want children, do I need to bank sperm before treatment?
Watching first does not close doors

If active surveillance is one of your options and you choose it, surgery, radiation, and the other paths all stay open. Many men watch a low-risk cancer for years and treat it only if it changes. Surgery and radiation, once done, do narrow what comes next, so it helps to know the order before you start.

Chapter 7 · Take these to your appointment

Good questions to ask your team

Print this page, or write these down. The space at the bottom is for your own questions.

  1. What is my NCCN risk group, and which of the five paths are options for me?
  2. Is active surveillance reasonable for my cancer? If so, what is the schedule, and what would make us switch to treatment?
  3. For my cancer, are surgery and radiation about equal on cancer control? Is there a reason to lean one way?
  4. If I have surgery, can you spare the nerves on one or both sides, and how many of these do you do a year?
  5. If I have radiation, which type fits my cancer? How many sessions? Would you add hormone therapy?
  6. Given my age and my health now, what are my own odds of leaking after treatment? What about erection trouble?
  7. Should my case be reviewed by both urology and radiation oncology, or at a tumor board?
  8. If I might still want children, how and when do I bank sperm?

My own questions:

Where this information comes from

  1. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 3.2026.
  2. European Association of Urology (EAU). Guidelines on Prostate Cancer, 2025.
  3. Hamdy FC, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer (ProtecT). New England Journal of Medicine, 2023.
  4. Hamdy FC, et al. Ten-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer (ProtecT). New England Journal of Medicine, 2016.
  5. Brand DH, et al. Stereotactic body radiotherapy versus conventionally fractionated radiotherapy (PACE-B). Lancet Oncology, 2019.
  6. Morris WJ, et al. Androgen suppression combined with elective nodal and dose-escalated radiation therapy, with or without a brachytherapy boost (ASCENDE-RT). International Journal of Radiation Oncology, Biology, Physics, 2017.
  7. Coughlin GD, et al. Robot-assisted versus open radical prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncology, 2018.
  8. WellPrept clinical brief: Localized Prostate Cancer, 2026-05-05 build, and the WellPrept localized prostate cancer patient guide.
This decision aid does not recommend one path over another. The numbers above reflect typical published ranges; your cancer, your risk group, your age, and your other health may make some paths more or less appropriate, and may take some off the table. Your urologist and your care team are the right people to translate this material to your situation.

WellPrept Decision Aid · localized-prostate-cancer-treatment-choice · v1 · next review 2027-06-09